TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16632462

Group type: EXPERIMENTAL
Intervention: Group VC+ (prior vaginal contraceptive)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Group VC- (no prior vaginal contraceptive)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both groups (VC+ and VC-)
Number of subjects: 190
Study: 14714835

Group type: EXPERIMENTAL
Intervention: Experimental heat-pressed lithium-disilicate glass-ceramic for crowns
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experimental heat-pressed lithium-disilicate glass-ceramic for inlays
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cementation process
Number of subjects: 16
Study: 11019371

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol diphosphate (DES-P) 300 mg daily for 2 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) 100 mg daily for 2 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 49
Study: 10323113

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methadone 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1472669

Group type: EXPERIMENTAL
Intervention: Guidewire technique for CVC insertion
Number of subjects: 128

Group type: COMPARATOR
Intervention: De novo catheterization at a different site
Number of subjects: 128
Study: 6690656

Group type: EXPERIMENTAL
Intervention: Feeding of 24 Cal/oz formula (Similac Special Care)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Feeding of 20 Cal/oz formula (Similac Special Care)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Feeding of 13 Cal/oz formula (Similac Special Care)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Feeding of 6.5 Cal/oz formula (Similac Special Care)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Feeding of distilled water (0 Cal/oz)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher caloric density feedings
Number of subjects: 10
Study: 30649388

Group type: EXPERIMENTAL
Intervention: CBT and neuromuscular exercise (FIT Teens)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 40
Study: 30341990

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1739

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1739

Group type: EXPERIMENTAL
Intervention: Galcanezumab (both doses)
Number of subjects: 1739
Study: 25619411

Group type: EXPERIMENTAL
Intervention: NLFU + SOC (non-contact low-frequency ultrasound therapy combined with standard of care)
Number of subjects: 36

Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NLFU + SOC
Number of subjects: 36

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 36
Study: 24758374

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Pneumothorax/Hemothorax
Number of subjects: 1790
Study: 22226517

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with capecitabine (1000 mg/m² twice daily on days 1 to 14 of each cycle) plus oxaliplatin (130 mg/m² on day 1 of each cycle) for 6 months
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with capecitabine plus oxaliplatin
Number of subjects: 1035
Study: 18719041

Group type: EXPERIMENTAL
Intervention: Combination antipsychotic prescribing (CAP)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Co-prescribed patients
Number of subjects: 363
Study: 17230206

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) at a subcutaneous daily dose of 10 microg/kg for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF)
Number of subjects: 0
Study: 15302193

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 168

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 168
Study: 12162586

Group type: COMPARATOR
Intervention: Brinzolamide 1%, Timolol 0.5%, Betaxolol 0.5%, Brimonidine 0.2%, Latanoprost 0.005% (in healthy volunteers)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%, Non-selective topical beta receptor blockers, Latanoprost 0.005% (in glaucoma patients)
Number of subjects: 22
Study: 9748678

Group type: EXPERIMENTAL
Intervention: Three additional mid biopsies
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sextant biopsies only
Number of subjects: 59
Study: 7936279

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 3203067

Group type: EXPERIMENTAL
Intervention: Ultraviolet B radiation (UVB) for 8 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.8 of the minimal erythema dose (MED) of UVB for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Visible light (placebo) for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.4 of the minimal erythema dose (MED) of UVB for 8 weeks
Number of subjects: 42
Study: 31971032

Group type: EXPERIMENTAL
Intervention: BR (Bendamustine and Rituximab)
Number of subjects: 146

Group type: COMPARATOR
Intervention: R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)
Number of subjects: 146
Study: 29747352

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27179257

Group type: EXPERIMENTAL
Intervention: Traditional clinic-based therapy + computer-based program (Rannan)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional clinic-based therapy
Number of subjects: 26
Study: 25330012

Group type: COMPARATOR
Intervention: Induction chemotherapy in group I
Number of subjects: 33

Group type: COMPARATOR
Intervention: Not applicable (group II)
Number of subjects: 33
Study: 23900005

Group type: EXPERIMENTAL
Intervention: Regional Specific Training Stimulus (RSTS) for 4 weeks followed by 8 weeks of progressive whole-body training (aerobic plus resistance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerobic exercise for 4 weeks followed by 8 weeks of progressive whole-body training (aerobic plus resistance)
Number of subjects: 0
Study: 20401474

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg per week)
Number of subjects: 12949

Group type: EXPERIMENTAL
Intervention: Bevacizumab (2.5 mg/kg per week)
Number of subjects: 12949

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg per week) in renal cell carcinoma patients
Number of subjects: 12949

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg per week) in breast cancer patients
Number of subjects: 12949
Study: 18712656

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 12
Study: 17053881

Group type: EXPERIMENTAL
Intervention: ZEEP (zero PEEP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: PEEP (8 cmH(2)O)
Number of subjects: 21
Study: 12812358

Group type: EXPERIMENTAL
Intervention: OptiMAL test
Number of subjects: 930

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: OptiMAL test for P. falciparum
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: OptiMAL test for P. vivax
Number of subjects: 930
Study: 15327040

Group type: EXPERIMENTAL
Intervention: Cannabis extract (2.5 mg THC and 0.9 mg CBD), dosage escalated from 15 to 30 mg THC over 14 days.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 9925088

Group type: EXPERIMENTAL
Intervention: P829 scintigraphy
Number of subjects: 30
Study: 8567841

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progesterone and ATP
Number of subjects: 0

Group type: COMPARATOR
Intervention: MH61 bead binding
Number of subjects: 0
Study: 2107780

Group type: EXPERIMENTAL
Intervention: Continuous intravenous prostacyclin (epoprostenol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional therapy (anticoagulants, oral vasodilators, and diuretics)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous intravenous prostacyclin (epoprostenol) for up to 18 months
Number of subjects: 24
Study: 7462528

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 28189429

Group type: EXPERIMENTAL
Intervention: Current regular aspirin (>3 tablets/week)
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Past regular aspirin
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Current postdiagnostic aspirin
Number of subjects: 22071
Study: 25431855

Group type: EXPERIMENTAL
Intervention: Digital media application on mobile phones showing inhalation therapy steps
Number of subjects: 66

Group type: COMPARATOR
Intervention: Written information only
Number of subjects: 66
Study: 23545102

Group type: EXPERIMENTAL
Intervention: Behavioral therapy plus 10 sessions of parasacral transcutaneous electrical neural stimulation (20 minutes, 10 Hz, 700 μs pulse, intensity based on sensitivity threshold, 3 times weekly for 10 sessions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Behavioral therapy (control group)
Number of subjects: 45
Study: 21419290

Group type: EXPERIMENTAL
Intervention: Buccal plus palatal infiltration (1.8 mL buccal + 0.5 mL palatal of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Buccal infiltration (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40
Study: 18291465

Group type: EXPERIMENTAL
Intervention: Chlorhexidine for 3 minutes followed by povidone-iodine for 30 seconds
Number of subjects: 100
Study: 17387194

Group type: EXPERIMENTAL
Intervention: Apical suction device
Number of subjects: 45

Group type: COMPARATOR
Intervention: Posterior pericardial suture
Number of subjects: 45
Study: 15490822

Group type: EXPERIMENTAL
Intervention: ECG spatial phase analysis in isthmus-dependent AFL
Number of subjects: 33

Group type: COMPARATOR
Intervention: ECG spatial phase analysis in nonisthmus-dependent AFL
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ECG spatial phase analysis in AF
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ECG spatial phase analysis in VT-MM
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ECG spatial phase analysis in VF
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ECG spatial phase analysis in other SVT
Number of subjects: 33
Study: 11574510

Group type: EXPERIMENTAL
Intervention: ZPTV measurement
Number of subjects: 86

Group type: COMPARATOR
Intervention: Classic embryo morphology score
Number of subjects: 86
Study: 9121505

Group type: EXPERIMENTAL
Intervention: Myoblast implantation (100 million myoblasts in the anterior tibial muscle)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg/kg/day) for 7 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (in the other leg)
Number of subjects: 10
Study: 7939998

Group type: EXPERIMENTAL
Intervention: Patients with low back pain
Number of subjects: 200

Group type: COMPARATOR
Intervention: Volunteers
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (Patients and Volunteers)
Number of subjects: 200
Study: 3128054

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin infusion (75 mg/10 h)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 31821065

Group type: EXPERIMENTAL
Intervention: BEP treatment (bleomycin‐etoposide‐cisplatin; n = 1,819)
Number of subjects: 5185

Group type: EXPERIMENTAL
Intervention: Radiotherapy (n = 780)
Number of subjects: 5185

Group type: EXPERIMENTAL
Intervention: Surveillance (n = 3,332)
Number of subjects: 5185
Study: 31326523

Group type: EXPERIMENTAL
Intervention: MIND foods and speed of processing training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (non-MIND foods and control games)
Number of subjects: 180
Study: 28520618

Group type: EXPERIMENTAL
Intervention: Standard care plus modified directly administered antiretroviral therapy (intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentration <2.35 ng/mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atazanavir hair concentration >2.35 ng/mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Participants with virological failure
Number of subjects: 50
Study: 25600198

Group type: EXPERIMENTAL
Intervention: Intravitreal injections with no antibiotic use
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Intravitreal injections with preinjection antibiotics only
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Intravitreal injections with postinjection antibiotics only
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Intravitreal injections with preinjection and postinjection antibiotics
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Affected eyes (11 eyes with endophthalmitis)
Number of subjects: 1185
Study: 23916577

Group type: EXPERIMENTAL
Intervention: Flow confirmation study (FCS)
Number of subjects: 66
Study: 21862744

Group type: EXPERIMENTAL
Intervention: Intensive dietary portfolio (7 clinic visits over 6 months)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Routine dietary portfolio (2 clinic visits over 6 months)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control diet (low-saturated fat therapeutic diet)
Number of subjects: 351
Study: 19764942

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a 5-grass pollen mixture, ultra-rush titration with doses of 30, 90, 150, and 300 IR every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons.
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 17607561

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy after routine clinical assessment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (decubitus care and tracheal suctioning)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Chest physiotherapy and Control group
Number of subjects: 180
Study: 15224283

Group type: EXPERIMENTAL
Intervention: Comprehensive program (8-session multicomponent program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief program (single session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study: 12174058

Group type: EXPERIMENTAL
Intervention: Topical arnica gel (applied twice a day for 2 weeks prior to laser treatment)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Topical arnica gel (applied twice a day for 2 weeks after laser treatment)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vehicle (applied twice a day for 2 weeks prior to laser treatment)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vehicle (applied twice a day for 2 weeks after laser treatment)
Number of subjects: 19
Study: 9667702

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy within 24 hours
Number of subjects: 104

Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy 6-8 weeks later
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 104
Study: 7658007

Group type: COMPARATOR
Intervention: CVC bandage changed once a week (OAW)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CVC bandage changed twice a week (TAW)
Number of subjects: 32
Study: 2568529

Group type: EXPERIMENTAL
Intervention: APACHE-II score at admission
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: APACHE-II score after 48 hours
Number of subjects: 290

Group type: COMPARATOR
Intervention: Ranson score after 48 hours
Number of subjects: 290

Group type: COMPARATOR
Intervention: Imrie score after 48 hours
Number of subjects: 290
Study: 141326

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and cyclophosphamide
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Oral estramustine phosphate
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: DTIC
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Leo 1031
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 360
Study: 30543311

Group type: EXPERIMENTAL
Intervention: Single mass drug administration of azithromycin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control arm (no treatment)
Number of subjects: 96
Study: 28254099

Group type: EXPERIMENTAL
Intervention: Acupuncture (8 sections, once a week for 30 minutes)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 25945013

Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion combined with acupuncture (HMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mesalazine (MESA)
Number of subjects: 60
Study: 22162138

Group type: EXPERIMENTAL
Intervention: Colposcopy with normal transformation zone (TZ)
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Colposcopy with abnormal transformation zone (TZ)
Number of subjects: 989

Group type: COMPARATOR
Intervention: Colposcopy (both groups)
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Colposcopy with normal TZ
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Colposcopy with abnormal TZ
Number of subjects: 989
Study: 21819581

Group type: EXPERIMENTAL
Intervention: Routine manual hyperinflation (MH) performed within 30 minutes after ICU admission and every 6 hours thereafter, before tracheal extubation.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (MH performed only if audible sputum present or SpO2 dropped below 92%).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Routine manual hyperinflation (MH) group.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 100
Study: 19594224

Group type: EXPERIMENTAL
Intervention: Green tea extract plus hypocaloric diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hypocaloric diet only
Number of subjects: 100
Study: 16317317

Group type: EXPERIMENTAL
Intervention: Sertindole (12-24 mg/day)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Risperidone (4-10 mg/day)
Number of subjects: 187
Study: 15207927

Group type: EXPERIMENTAL
Intervention: Bipolar I Disorder subjects
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 11132739

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8986513

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-treatment manual followed by up to 8 weeks of CBT (sequential group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study: 8375517

Group type: EXPERIMENTAL
Intervention: Vaginal ultrasound and blood samples for hormone parameters between 20 and 30 days after conception
Number of subjects: 0
Study: 3739879

Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg orally
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Diltiazem, 90 mg orally
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg orally
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Coronary arteriography during attacks
Number of subjects: 101
Study: 30028245

Group type: EXPERIMENTAL
Intervention: Soy milk (240 ml daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (low-calorie diet only)
Number of subjects: 70
Study: 30846916

Group type: EXPERIMENTAL
Intervention: Scapulothoracic mobilization + Physical Therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 46
Study: 27020488

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100μg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ephedrine 8mg
Number of subjects: 106
Study: 24901060

Group type: EXPERIMENTAL
Intervention: CBT-based psychoeducational intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 22466411

Group type: EXPERIMENTAL
Intervention: Passive stretch of ankle extensors at 20°/s
Number of subjects: 10

Group type: COMPARATOR
Intervention: Static ankle angles (99, 98, 94, and 90° of flexion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower stimulus intensity (20 % Mmax) during passive stretch
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher stimulus intensity (Hmax) during passive stretch
Number of subjects: 10
Study: 20617290

Group type: EXPERIMENTAL
Intervention: 500 mg of ascorbic acid and 400 IU of alpha-tocopherol (Tx1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1,000 mg of ascorbic acid and 400 IU of alpha-tocopherol (Tx2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (Tx0)
Number of subjects: 90
Study: 18595465

Group type: EXPERIMENTAL
Intervention: Synbiotics (Normoflorin B and Normoflorin L)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no synbiotics)
Number of subjects: 48
Study: 15601345

Group type: EXPERIMENTAL
Intervention: ELA-Max (30 min application)
Number of subjects: 60

Group type: COMPARATOR
Intervention: EMLA (60 min application)
Number of subjects: 60
Study: 11235924

Group type: EXPERIMENTAL
Intervention: Nefazodone (400 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sertraline (100 mg/day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 105
Study: 9553535

Group type: EXPERIMENTAL
Intervention: Cemented bipolar hemiarthroplasty
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cemented unipolar hemiarthroplasty
Number of subjects: 47
Study: 7846199

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prepulse+pulse
Number of subjects: 12
Study: 3058014

Group type: EXPERIMENTAL
Intervention: Verapamil administered three times daily (t.i.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Verapamil administered twice daily (b.i.d.)
Number of subjects: 15
Study: 791322

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sulphaphenazole
Number of subjects: 12